Reports Q3 revenue $33.25M, consensus $32.52M. As of September 30, cash, cash equivalents and short-term investments were approximately $298.4M, as compared to $275.8M as of December 31, 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- RYTM Upcoming Earnings Report: What to Expect?
- 3 Best Stocks to Buy Now, 10/30/2024, According to Top Analysts
- Rhythm Pharmaceuticals and Axovia Therapeutics sign BBS research collaboration
- Rhythm Pharmaceuticals price target raised to $52 from $48 at BofA
- Biotech Alert: Searches spiking for these stocks today